Allspring Global Investments Holdings LLC Raises Stock Holdings in Perrigo Company plc (NYSE:PRGO)

Allspring Global Investments Holdings LLC boosted its position in shares of Perrigo Company plc (NYSE:PRGO - Free Report) by 5.1% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 1,092,398 shares of the company's stock after acquiring an additional 52,696 shares during the quarter. Allspring Global Investments Holdings LLC owned 0.80% of Perrigo worth $28,402,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. Pacer Advisors Inc. boosted its stake in shares of Perrigo by 2.1% during the 4th quarter. Pacer Advisors Inc. now owns 20,337 shares of the company's stock worth $523,000 after acquiring an additional 427 shares during the last quarter. Wealth Enhancement Advisory Services LLC lifted its position in Perrigo by 2.1% during the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 21,617 shares of the company's stock valued at $567,000 after purchasing an additional 436 shares in the last quarter. Voisard Asset Management Group Inc. grew its holdings in Perrigo by 9.7% during the third quarter. Voisard Asset Management Group Inc. now owns 5,100 shares of the company's stock valued at $134,000 after purchasing an additional 450 shares during the period. Central Pacific Bank Trust Division increased its position in Perrigo by 33.3% in the fourth quarter. Central Pacific Bank Trust Division now owns 2,000 shares of the company's stock worth $51,000 after buying an additional 500 shares in the last quarter. Finally, Creative Planning raised its stake in shares of Perrigo by 3.7% in the third quarter. Creative Planning now owns 18,477 shares of the company's stock worth $485,000 after buying an additional 661 shares during the period. Institutional investors own 95.91% of the company's stock.

Insider Buying and Selling at Perrigo

In other Perrigo news, Director Jeffrey B. Kindler sold 17,598 shares of the business's stock in a transaction on Monday, December 9th. The shares were sold at an average price of $28.27, for a total value of $497,495.46. Following the sale, the director now owns 5,409 shares in the company, valued at $152,912.43. The trade was a 76.49 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 0.40% of the company's stock.

Perrigo Price Performance

Shares of NYSE:PRGO traded up $0.67 during trading on Wednesday, hitting $24.81. 1,142,496 shares of the company's stock were exchanged, compared to its average volume of 1,261,383. The business's 50-day simple moving average is $25.11 and its 200 day simple moving average is $26.30. The company has a debt-to-equity ratio of 0.94, a current ratio of 2.56 and a quick ratio of 1.77. Perrigo Company plc has a 52-week low of $23.14 and a 52-week high of $33.46. The company has a market cap of $3.38 billion, a price-to-earnings ratio of -21.20 and a beta of 0.54.

Analyst Ratings Changes

A number of research analysts recently issued reports on the company. StockNews.com upgraded Perrigo from a "hold" rating to a "buy" rating in a research note on Monday, February 10th. Argus lowered shares of Perrigo from a "buy" rating to a "hold" rating in a research report on Tuesday, January 14th. Finally, Piper Sandler cut shares of Perrigo from an "overweight" rating to a "neutral" rating and reduced their price objective for the stock from $34.00 to $27.00 in a research note on Monday, January 6th. Three research analysts have rated the stock with a hold rating and three have given a buy rating to the company's stock. According to data from MarketBeat.com, Perrigo presently has a consensus rating of "Moderate Buy" and an average price target of $35.00.

Perrigo Company Profile

Perrigo Company plc provides over-the-counter health and wellness solutions to enhance individual well-being in the United States, Europe, and internationally. It operates through Consumer Self-Care Americas and Consumer Self-Care International segments. The company develops, manufactures, markets, and distributes self-care consumer products, such as upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and nutritional beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers.